A Manhattan federal judge has ruled that the U.S. Supreme Court's recent Stoneridge ruling does not shield from securities fraud claims a Bristol-Myers Squibb executive who made no public statements but whose behavior is central to the company's alleged misconduct. Bristol-Myers shareholders are suing the company and two of its top executives for allegedly misleading them about patent litigation against Apotex, a generic version of Bristol-Myers' best-selling Plavix blood-thinning drug.
Despite 'Stoneridge,' Fraud Claims Proceed Against Bristol-Myers Executive
New York Law Journal
August 22, 2008